Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion

With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization